GlassScriptPhysician profile
Christopher S Lathan
NPI 1295713048
$16,081.60
in general payments reported to CMS, 2019-2025
6 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $8,470 · 2022: $24.19 · 2023: $4,445 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,845 · Food and Beverage: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,845.00 |
| Food and Beverage | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,890.00 | 2020-2023 | |
| Eli Lilly and Company | $4,025.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $2,460.00 | 2025 | |
| Lilly USA, LLC | $575.00 | 2019 | |
| Bristol Myers Squibb Company | $107.41 | 2019 | |
| Janssen Scientific Affairs, LLC | $24.19 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.